JP2012510475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510475A5 JP2012510475A5 JP2011538728A JP2011538728A JP2012510475A5 JP 2012510475 A5 JP2012510475 A5 JP 2012510475A5 JP 2011538728 A JP2011538728 A JP 2011538728A JP 2011538728 A JP2011538728 A JP 2011538728A JP 2012510475 A5 JP2012510475 A5 JP 2012510475A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- nhr
- group
- transition metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 181
- 125000000217 alkyl group Chemical group 0.000 claims description 76
- 229910052723 transition metal Inorganic materials 0.000 claims description 76
- 150000003624 transition metals Chemical class 0.000 claims description 76
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 73
- 239000013522 chelant Substances 0.000 claims description 70
- -1 dioxolopyridinyl Chemical group 0.000 claims description 69
- 125000000623 heterocyclic group Chemical group 0.000 claims description 60
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 52
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 48
- 125000002757 morpholinyl group Chemical group 0.000 claims description 47
- 125000003386 piperidinyl group Chemical group 0.000 claims description 47
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 46
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 36
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 34
- 125000001188 haloalkyl group Chemical group 0.000 claims description 33
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 32
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 31
- 125000004076 pyridyl group Chemical group 0.000 claims description 31
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- 125000001544 thienyl group Chemical group 0.000 claims description 26
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 25
- 125000002541 furyl group Chemical group 0.000 claims description 25
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 24
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 24
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 24
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 24
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 24
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 24
- NELREAXCVQVNGC-UHFFFAOYSA-N ethynethiolate Chemical group [S]C#[C] NELREAXCVQVNGC-UHFFFAOYSA-N 0.000 claims description 24
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 24
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 17
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 16
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 16
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 16
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 12
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 4
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 4
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims description 4
- 125000005016 hydroxyalkynyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 claims description 2
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 claims description 2
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 claims description 2
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 claims description 2
- OOKIODJYZSVHDO-QMYFOHRPSA-N (2s)-n-tert-butyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NC(C)(C)C)CCC1 OOKIODJYZSVHDO-QMYFOHRPSA-N 0.000 claims description 2
- OFPZNTXZCGKCMU-VXUABRCOSA-N (3z,5e,7r,8r,10r,11z,13r,14s,15s,21r,22r)-22-[(2r,3z)-hexa-3,5-dien-2-yl]-8,10,14,20-tetrahydroxy-7,13,15,17,21-pentamethyl-1-oxacyclodocosa-3,5,11-trien-2-one Chemical compound C=C\C=C/[C@@H](C)[C@H]1OC(=O)\C=C/C=C/[C@@H](C)[C@H](O)C[C@@H](O)\C=C/[C@@H](C)[C@@H](O)[C@@H](C)CC(C)CCC(O)[C@H]1C OFPZNTXZCGKCMU-VXUABRCOSA-N 0.000 claims description 2
- SCJGXQSJGQUCFA-YSMBQZINSA-N 2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]aniline;hydrochloride Chemical compound Cl.C1=C(N)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 SCJGXQSJGQUCFA-YSMBQZINSA-N 0.000 claims description 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- OFPZNTXZCGKCMU-QUQSCIKMSA-N Dictyostatin 1 Natural products CC(C=C/C=C)C1OC(=O)C=C/C=C/C(C)C(O)CC(O)C=C/C(C)C(O)C(C)CC(C)CCC(O)C1C OFPZNTXZCGKCMU-QUQSCIKMSA-N 0.000 claims description 2
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 claims description 2
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 claims description 2
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 claims description 2
- UKIMCRYGLFQEOE-UHFFFAOYSA-N Epothilone F Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2(C)OC2CC1C(C)=CC1=CSC(CO)=N1 UKIMCRYGLFQEOE-UHFFFAOYSA-N 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102000029749 Microtubule Human genes 0.000 claims description 2
- 108091022875 Microtubule Proteins 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 229940028652 abraxane Drugs 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- WIUSFZNUZWLLDZ-UHFFFAOYSA-N caribaeolin Natural products C1=CC(OC)(C(=CC2C(C(C=CC2C(C)C)(C)O)C2)COC(C)=O)OC1(C)C2OC(=O)C=CC1=CN(C)C=N1 WIUSFZNUZWLLDZ-UHFFFAOYSA-N 0.000 claims description 2
- KGOMYXIKIJGWKS-UHFFFAOYSA-N caribaeoside Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(C=CC1C(C)C)(C)O)C1C=C2COC1OCC(O)C(O)C1OC(C)=O KGOMYXIKIJGWKS-UHFFFAOYSA-N 0.000 claims description 2
- KGOMYXIKIJGWKS-DKNGGRFKSA-N chembl1916173 Chemical compound C(/[C@H]1[C@H]([C@](C=C[C@@H]1C(C)C)(C)O)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O KGOMYXIKIJGWKS-DKNGGRFKSA-N 0.000 claims description 2
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 claims description 2
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims description 2
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims description 2
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 claims description 2
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims description 2
- FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 claims description 2
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 claims description 2
- UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- IKIBJHWXDSKRKV-UHFFFAOYSA-N fijianolide B Natural products CC1CC(=C)CC(O)C2OC2CC(OC(=O)C=C/CC3OC(C)(CC=C3)C1)C(O)C=CC4CC(=CCO4)C IKIBJHWXDSKRKV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 claims description 2
- MSBQEQDLFWWWMV-XZZGLLCESA-N laulimalide Chemical compound C(/[C@H](O)[C@H]1OC(=O)\C=C/C[C@@H]2C=CC[C@H](O2)C[C@H](CC(=C)C[C@H](O)[C@@H]2O[C@H]2C1)C)=C\[C@@H]1CC(C)=CCO1 MSBQEQDLFWWWMV-XZZGLLCESA-N 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 210000004688 microtubule Anatomy 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 229930182947 sarcodictyin Natural products 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229930194539 taccalonolide Natural products 0.000 claims description 2
- 108010029464 tasidotin Proteins 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 239000003205 fragrance Substances 0.000 claims 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 claims 1
- GVOUFPWUYJWQSK-UHFFFAOYSA-N Cyclofenil Chemical group C1=CC(OC(=O)C)=CC=C1C(C=1C=CC(OC(C)=O)=CC=1)=C1CCCCC1 GVOUFPWUYJWQSK-UHFFFAOYSA-N 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 229960002944 cyclofenil Drugs 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 0 CSC(c1ccccc1)N(*)N*C*([N-][N+](*)CCSC*)=O Chemical compound CSC(c1ccccc1)N(*)N*C*([N-][N+](*)CCSC*)=O 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20052608P | 2008-12-01 | 2008-12-01 | |
| US61/200,526 | 2008-12-01 | ||
| PCT/US2009/066211 WO2010065512A2 (en) | 2008-12-01 | 2009-12-01 | Compounds for treating proliferative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012510475A JP2012510475A (ja) | 2012-05-10 |
| JP2012510475A5 true JP2012510475A5 (enExample) | 2013-05-16 |
| JP5631327B2 JP5631327B2 (ja) | 2014-11-26 |
Family
ID=42109975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011538728A Expired - Fee Related JP5631327B2 (ja) | 2008-12-01 | 2009-12-01 | 増殖性障害を治療するための化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8680100B2 (enExample) |
| EP (1) | EP2370402A2 (enExample) |
| JP (1) | JP5631327B2 (enExample) |
| AU (1) | AU2009322603B2 (enExample) |
| CA (1) | CA2745065A1 (enExample) |
| WO (1) | WO2010065512A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010501562A (ja) | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | 増殖性障害を治療するための化合物 |
| US8618170B2 (en) | 2007-11-09 | 2013-12-31 | Synta Pharmaceuticals Corp. | Oral formulations of bis(thiohydrazide amides) |
| WO2009105257A1 (en) | 2008-02-21 | 2009-08-27 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| US8633323B2 (en) * | 2008-03-31 | 2014-01-21 | Synta Pharmaceuticals Corp. | Process for preparing bis(thiohydrazide amides) |
| KR20110081300A (ko) | 2008-10-22 | 2011-07-13 | 신타 파마슈티칼스 코프. | 비스[티오하이드라자이드 아미드] 화합물의 전이금속 복합물 |
| KR20110073613A (ko) | 2008-10-22 | 2011-06-29 | 신타 파마슈티칼스 코프. | 비스(티오하이드라자이드 아마이드) 화합물의 전이금속착체 |
| WO2010065512A2 (en) | 2008-12-01 | 2010-06-10 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| US8822532B2 (en) | 2009-12-04 | 2014-09-02 | Synta Pharmaceuticals Corp. | Bis[thiohydrazide amide] compounds for treating leukemia |
| EP2560627A1 (en) | 2010-04-20 | 2013-02-27 | Synta Pharmaceuticals Corp. | Use of bis [thiohydrazide amide]compounds such as elesclomol for treating cancers |
| JP2016511218A (ja) * | 2012-10-15 | 2016-04-14 | チャマエレオ ファーマ ビーブイビーエー | がんを処置するためのサルフェストロール |
| US9244345B1 (en) | 2014-11-06 | 2016-01-26 | International Business Machines Corporation | Non-ionic photo-acid generating polymers for resist applications |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS583499B2 (ja) | 1975-07-28 | 1983-01-21 | 旭化成株式会社 | アンテイカサレタ ポリウレタンソセイブツ |
| TWI332943B (en) | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI252847B (en) | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
| US6924312B2 (en) | 2001-07-10 | 2005-08-02 | Synta Pharmaceuticals Corp. | Taxol enhancer compounds |
| TWI297335B (en) | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI330079B (en) | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
| RU2406722C2 (ru) | 2004-06-23 | 2010-12-20 | Синта Фармасьютикалс Корп. | Соли бис-(тиогидразидамида) для лечения рака |
| WO2006033913A2 (en) | 2004-09-16 | 2006-03-30 | Synta Pharmaceuticals Corp. | Bis (thio-hydrazide amides) for treament of hyperplasia |
| US8148426B2 (en) | 2004-11-19 | 2012-04-03 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amides) for increasing Hsp70 expression |
| WO2006062732A2 (en) | 2004-11-19 | 2006-06-15 | Synta Pharmaceuticals Corp. | Compounds acting at the centrosome |
| CA2604907A1 (en) | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Combination cancer therapy with bis(thiohydrazide) amide compounds |
| CA2603314A1 (en) | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Methods of increasing natural killer cell activity for therapy |
| BRPI0611262A2 (pt) | 2005-05-16 | 2010-08-24 | Synta Pharmaceuticals Corp | mÉtodos de preparaÇço de um di-sal de bis (tio-hidrazida amida) |
| AU2006279891B2 (en) | 2005-08-16 | 2010-03-11 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amide) formulation |
| US20080226588A1 (en) | 2006-08-21 | 2008-09-18 | Mcleod Matthew | Treating melanoma with bis(thiohydrazide amides) |
| WO2008024301A2 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma |
| JP2010501562A (ja) | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | 増殖性障害を治療するための化合物 |
| WO2008024304A2 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Compounds for treatment of proliferative disorders |
| JP2010501558A (ja) | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | 癌を治療するためのビス（チオヒドラジドアミド）との組み合わせ |
| CA2661440A1 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| AU2007290490B2 (en) | 2006-08-31 | 2011-09-08 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
| AU2007294969A1 (en) | 2006-09-11 | 2008-03-20 | Synta Pharmaceuticals Corp. | Bis (thiohydrazide amides) formulation |
| US7645904B2 (en) | 2006-09-15 | 2010-01-12 | Synta Pharmaceuticals Corp. | Purification of bis(thiohydrazide amides) |
| US20090093538A1 (en) | 2007-01-03 | 2009-04-09 | Synta Pharmaceuticals Corp | Method for treating cancer |
| US8093425B2 (en) | 2007-04-30 | 2012-01-10 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| WO2009020631A2 (en) | 2007-08-07 | 2009-02-12 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| US8637704B2 (en) | 2007-11-28 | 2014-01-28 | Synta Pharmaceuticals Corp. | Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide) |
| WO2009105257A1 (en) | 2008-02-21 | 2009-08-27 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| US8633323B2 (en) | 2008-03-31 | 2014-01-21 | Synta Pharmaceuticals Corp. | Process for preparing bis(thiohydrazide amides) |
| KR20110081300A (ko) | 2008-10-22 | 2011-07-13 | 신타 파마슈티칼스 코프. | 비스[티오하이드라자이드 아미드] 화합물의 전이금속 복합물 |
| KR20110073613A (ko) | 2008-10-22 | 2011-06-29 | 신타 파마슈티칼스 코프. | 비스(티오하이드라자이드 아마이드) 화합물의 전이금속착체 |
| WO2010065512A2 (en) | 2008-12-01 | 2010-06-10 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
-
2009
- 2009-12-01 WO PCT/US2009/066211 patent/WO2010065512A2/en not_active Ceased
- 2009-12-01 JP JP2011538728A patent/JP5631327B2/ja not_active Expired - Fee Related
- 2009-12-01 AU AU2009322603A patent/AU2009322603B2/en not_active Ceased
- 2009-12-01 EP EP09765191A patent/EP2370402A2/en not_active Withdrawn
- 2009-12-01 CA CA2745065A patent/CA2745065A1/en not_active Abandoned
- 2009-12-01 US US13/132,106 patent/US8680100B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012510475A5 (enExample) | ||
| AU2006214164B2 (en) | Isoxazole combretastin derivatives for the treatment of disorders | |
| EP2751112B1 (en) | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof | |
| AU2006272652B2 (en) | 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders | |
| EP2054059A2 (en) | Triazole compounds that modulate hsp90 activity | |
| RS20050106A (sr) | Kombinovana terapija hiperproliferativnih bolesti | |
| CA2975223C (en) | Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer | |
| JP2013516393A5 (enExample) | ||
| JP2012506443A5 (enExample) | ||
| JP2008545670A (ja) | 疾患を処置するためのジアリールウレア類を含む組合せ治療 | |
| US8399435B2 (en) | Compounds for the treatment of proliferative disorders | |
| CA2913736A1 (en) | Compounds and methods of treating cancer | |
| JP2025118609A (ja) | Ｎｕｒｒ１受容体調節因子 | |
| JP2010540649A5 (enExample) | ||
| KR101589837B1 (ko) | 디히드록시 치환기를 포함하는 trpv1 길항제 및 그의 용도 | |
| EP3366687A1 (en) | Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis | |
| EP4244205A1 (en) | Ire1alpha inhibitors and uses thereof | |
| WO2013152032A1 (en) | Compositions and methods for treating cancer |